HSA
LGND icon

Hussman Strategic Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Hussman Strategic Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,336
Closed -$803K – 339
2021
Q4 		$803K Buy
+8,336
New +$770K 0.18% 183

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Hussman Strategic Advisors's LGND Position: Q1 2022 in Review

Hussman Strategic Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2022, closing a stake of 8,336 shares — an estimated $803K sold.

Hussman Strategic Advisors first reported a position in LGND in Q4 2021 and held it in 1 quarter. The position peaked at $803K in Q4 2021. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

  • Hussman Strategic Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Hussman Strategic Advisors sold 8,336 Ligand Pharmaceuticals shares in Q1 2022, an estimated $803K.
  • Hussman Strategic Advisors first reported a position in Ligand Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Hussman Strategic Advisors's Ligand Pharmaceuticals position peaked at $803K in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on Hussman Strategic Advisors's 13F filing for Q1 2022, filed 4 May 2022.